[44] Buscail L, Saint-Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823–7. [45] Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729–36. [46] Plonowski A, Schally AV, Letsch M, et al. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoural IGF-II and vascular endothelial growth factor. Prostate 2002;52:173–82. [47] Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides 2002;23: 1127–33. [48] Chopin LK, Herington AC. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 2001;49:116–21. [49] Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 2002;87:4707–14. [50] Schally AV, Varga JL. Antagonistic analogues of growth hormone-releasing hormone: new potential antitumour agents. Trends Endocrinol Metab 1999;10:383–91. [51] Havt A, Schally AV, Halmos G, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A 2005;102:17424–9. [52] Zarandi M, Varga JL, Schally AV, et al. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumour activities. Proc Natl Acad Sci U S A 2006;103:4610–5. [53] Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a ‘‘smarter’’ chemotherapy. Curr Pharm Design 2005;11: 1167–80.